SI3431475T1 - Trdne oblike selektivnega zaviralca CDK4/6 - Google Patents

Trdne oblike selektivnega zaviralca CDK4/6

Info

Publication number
SI3431475T1
SI3431475T1 SI201431819T SI201431819T SI3431475T1 SI 3431475 T1 SI3431475 T1 SI 3431475T1 SI 201431819 T SI201431819 T SI 201431819T SI 201431819 T SI201431819 T SI 201431819T SI 3431475 T1 SI3431475 T1 SI 3431475T1
Authority
SI
Slovenia
Prior art keywords
inhibitor
solid forms
selective cdk4
cdk4
selective
Prior art date
Application number
SI201431819T
Other languages
English (en)
Inventor
Brian Patrick Chekal
Nathan D. Ide
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50151343&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3431475(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI3431475T1 publication Critical patent/SI3431475T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201431819T 2013-02-21 2014-02-08 Trdne oblike selektivnega zaviralca CDK4/6 SI3431475T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767761P 2013-02-21 2013-02-21
EP18186675.7A EP3431475B1 (en) 2013-02-21 2014-02-08 Solid forms of a selective cdk4/6 inhibitor

Publications (1)

Publication Number Publication Date
SI3431475T1 true SI3431475T1 (sl) 2021-08-31

Family

ID=50151343

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201431819T SI3431475T1 (sl) 2013-02-21 2014-02-08 Trdne oblike selektivnega zaviralca CDK4/6
SI201430929T SI2958916T1 (sl) 2013-02-21 2014-02-08 Trdne oblike selektivnih zaviralcev CDK4/6

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201430929T SI2958916T1 (sl) 2013-02-21 2014-02-08 Trdne oblike selektivnih zaviralcev CDK4/6

Country Status (24)

Country Link
US (2) US20160002223A1 (sl)
EP (2) EP3431475B1 (sl)
JP (3) JP6381016B2 (sl)
KR (2) KR101858913B1 (sl)
CN (3) CN107759594A (sl)
AR (1) AR094842A1 (sl)
AU (1) AU2014220354B2 (sl)
BR (1) BR112015019508A8 (sl)
CA (1) CA2900322C (sl)
CY (2) CY1120734T1 (sl)
DK (2) DK2958916T3 (sl)
ES (2) ES2694787T3 (sl)
HK (2) HK1248217A1 (sl)
HU (2) HUE054212T2 (sl)
IL (1) IL240277B (sl)
MX (2) MX363715B (sl)
PL (2) PL2958916T3 (sl)
PT (2) PT3431475T (sl)
RU (1) RU2619944C2 (sl)
SG (1) SG11201505680RA (sl)
SI (2) SI3431475T1 (sl)
TR (1) TR201816077T4 (sl)
TW (2) TWI670269B (sl)
WO (1) WO2014128588A1 (sl)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2872491T3 (pl) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitory receptora czynnika wzrostu fibroblastów
MX363715B (es) 2013-02-21 2019-03-29 Pfizer Formas solidas de un inhbidor de cdk4/6 selectivo.
DK3395814T3 (da) 2013-10-25 2022-07-04 Blueprint Medicines Corp Hæmmere af fibroblastvækstfaktorreceptoren
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US20170240543A1 (en) * 2014-08-14 2017-08-24 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
EP3186252A1 (en) * 2014-08-28 2017-07-05 ratiopharm GmbH Method of producing palbociclib and pharmaceutical compositions comprising the same
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
KR102369405B1 (ko) * 2015-06-04 2022-03-02 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
CN106397431A (zh) * 2015-07-28 2017-02-15 苏州国匡医药科技有限公司 一种抗肿瘤药物的新晶型及其制备方法和用途
CN105153149B (zh) * 2015-07-29 2017-09-19 江苏中邦制药有限公司 一种选择性激酶抑制剂Palbociclib的制备方法
EP3543235A1 (en) 2015-08-05 2019-09-25 ratiopharm GmbH Crystalline form and acetic acid adduct of palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN106608876B (zh) * 2015-10-21 2018-06-19 新发药业有限公司 一种高纯度帕博西尼的制备方法
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CN106632311B (zh) * 2015-11-02 2021-05-18 上海科胜药物研发有限公司 一种帕博西尼晶型a和晶型b的制备方法
CN106831759A (zh) * 2015-12-03 2017-06-13 上海星泰医药科技有限公司 帕布昔利布及其中间体的制备方法
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
CN105524059A (zh) * 2016-01-06 2016-04-27 北京修正创新药物研究院有限公司 一种帕波西比杂质的制备方法
GB201601329D0 (en) 2016-01-25 2016-03-09 Mohammad Mohammad A Inverse gas chromatography standard solutions, device and method
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) * 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN106336411B (zh) * 2016-04-27 2018-03-06 上海医药集团股份有限公司 Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
CN109661393A (zh) 2016-05-08 2019-04-19 上海诚妙医药科技有限公司 帕布昔利布的新晶型及其制备方法及其用途
CN105924439B (zh) * 2016-06-24 2017-11-24 石家庄海瑞药物科技有限公司 一种帕布昔利布的制备方法
CN106146494B (zh) * 2016-06-29 2018-02-06 重庆华邦制药有限公司 用于制备帕布昔利布a型晶的溶剂及制备方法
MX2019000246A (es) * 2016-07-07 2019-05-27 Plantex Ltd Formas en estado solido del dimesilato de palbociclib.
CN106220626A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种帕布昔利布的多晶型及其制备方法
CN106220627A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种高纯度帕布昔利布的工业化制备方法
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
WO2018065999A1 (en) 2016-10-07 2018-04-12 Mylan Laboratories Limited Novel polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
RU2019111887A (ru) * 2016-10-20 2020-11-20 Пфайзер Инк. Антипролиферативные средства для лечения лаг
CN108017630B (zh) * 2016-10-31 2022-10-11 上海创诺制药有限公司 一种小比表面积帕博西尼游离碱的制备方法
WO2018091999A1 (en) 2016-11-16 2018-05-24 Pfizer Inc. Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
CN108117550B (zh) * 2016-11-29 2020-08-14 上海医药工业研究院 吡啶并[2,3-d]嘧啶类化合物的制备方法
US10676474B2 (en) 2016-12-16 2020-06-09 Cstone Pharmaceuticals 1,6-naphthyridine derivatives as CDK4/6 inhibitor
CN110573183A (zh) * 2017-04-21 2019-12-13 上海方楠生物科技有限公司 一种帕博西林组合物及其制备方法
CN108864078B (zh) * 2017-05-10 2021-10-15 江苏豪森药业集团有限公司 帕博西尼晶型b的制备方法
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EA202090402A1 (ru) 2017-07-28 2020-05-19 Синтон Б.В. Фармацевтическая композиция, содержащая пальбоциклиб
EP3700908A1 (en) 2017-10-27 2020-09-02 Fresenius Kabi Oncology Ltd An improved process for the preparation of ribociclib and its salts
CN109897034A (zh) * 2017-12-07 2019-06-18 南京卡文迪许生物工程技术有限公司 一种高纯度晶型a帕布昔利布及其制备方法和药物组合物
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
EP3758753A1 (en) 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
CN108299422B (zh) * 2018-02-28 2019-10-25 杭州福斯特药业有限公司 一种帕泊昔利布中间体的制备方法
WO2019220253A1 (en) 2018-05-14 2019-11-21 Pfizer Inc. Oral solution formulation
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
SI3802529T1 (sl) 2018-05-24 2024-03-29 Synthon B.V. Postopek za izdelavo palbocikliba
WO2019238088A1 (zh) * 2018-06-13 2019-12-19 基石药业 吡啶并吡啶酮衍生物的盐型及晶型
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
BR112021007745A2 (pt) 2018-10-24 2021-07-27 Effector Therapeutics, Inc. formas cristalinas de inibidores de mnk
CN109336886A (zh) * 2018-12-07 2019-02-15 重庆三圣实业股份有限公司 一种帕博西尼的制备方法及其产品
BR112021013050A2 (pt) * 2019-01-17 2021-09-21 Pfizer Inc. Forma cristalina de um inibidor de cdk
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
CA3141531A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
US20230053328A9 (en) 2019-05-24 2023-02-16 Pfizer Inc. Combination therapies using cdk inhibitors
CN110256424A (zh) * 2019-07-03 2019-09-20 武汉工程大学 一种帕博西尼关键中间体v的合成方法
CN110551063A (zh) * 2019-10-17 2019-12-10 山东邹平大展新材料有限公司 一种合成5-(n-boc-哌嗪-1-基)吡啶-2-胺的方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
AU2021308406A1 (en) 2020-07-15 2023-02-23 Ctxt Pty Ltd KAT6 inhibitor methods and combinations for cancer treatment
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
CN112274493A (zh) * 2020-11-18 2021-01-29 石药集团中奇制药技术（石家庄）有限公司 一种哌柏西利胶囊的制备方法
CN112457311B (zh) * 2020-12-04 2022-07-12 江苏豪森药业集团有限公司 一种含有氯溴吡咯嘧啶酮结构化合物的制备方法
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN112661753B (zh) * 2020-12-29 2022-06-03 山东铂源药业股份有限公司 一种帕布昔利布中间体的制备方法
CN112778303A (zh) * 2020-12-31 2021-05-11 武汉九州钰民医药科技有限公司 Cdk4/6激酶抑制剂shr6390的制备方法
CN112898299B (zh) * 2021-01-26 2021-11-26 山东铂源药业有限公司 一种帕布昔利布中间体的制备方法
WO2022266070A1 (en) 2021-06-14 2022-12-22 Preh Holding, Llc Connected body surface care module
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
CN113999227A (zh) * 2021-11-26 2022-02-01 常州大学 一种帕博西尼中间体的制备方法
WO2023107525A1 (en) 2021-12-10 2023-06-15 Eli Lilly And Company Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302755A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024097206A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JPH11138004A (ja) * 1997-11-06 1999-05-25 Mitsui Chem Inc ニトリル水和用の銅触媒及びその調製方法
MXPA02008535A (es) * 2000-03-06 2002-12-13 Warner Lambert Co Inhibidores de 5-alquilpirido (2.3-d) pirimidinas tirosina quinasa.
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
JP2004074041A (ja) * 2002-08-20 2004-03-11 Cabot Supermetal Kk フッ素の回収方法
JP2004149472A (ja) * 2002-10-31 2004-05-27 Sumitomo Chem Co Ltd 亜リン酸エステル類の結晶、及びその製造方法
PL1648889T3 (pl) * 2003-07-11 2009-03-31 Warner Lambert Co Sól izetionian selektywnego inhibitora CDK4
MXPA06015003A (es) * 2004-06-29 2007-08-07 Sapphire Therapeutics Inc Formas cristalinas de 1,2,2-trimetilhidrazida de acido (3r)-1-(2-metilalanil-d-triptofil)-3-(fenilmetil)-3- piperidincarboxilico.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR20090052385A (ko) 2006-09-08 2009-05-25 화이자 프로덕츠 인크. 2-（피리딘-2-일아미노）-피리도［2,3-ｄ］피리미딘-7-온의합성
US8329695B2 (en) * 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
EP2453894B1 (en) * 2009-07-15 2015-11-04 Theravance Biopharma R&D IP, LLC Crystalline freebase form of a biphenyl compound
US8362014B2 (en) * 2009-09-20 2013-01-29 Abbvie Inc. ABT-263 crystalline forms
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
CN103347870A (zh) * 2010-11-09 2013-10-09 扎夫根股份有限公司 Metap-2抑制剂的结晶固体及其制备和使用方法
MX363715B (es) 2013-02-21 2019-03-29 Pfizer Formas solidas de un inhbidor de cdk4/6 selectivo.
US20170240543A1 (en) 2014-08-14 2017-08-24 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib

Also Published As

Publication number Publication date
JP2017186376A (ja) 2017-10-12
EP3431475A1 (en) 2019-01-23
PL3431475T3 (pl) 2021-09-13
IL240277B (en) 2019-10-31
CN107759594A (zh) 2018-03-06
RU2015132371A (ru) 2017-03-29
HUE040434T2 (hu) 2019-03-28
DK3431475T3 (da) 2021-05-25
TW201444834A (zh) 2014-12-01
EP2958916B1 (en) 2018-09-12
EP2958916A1 (en) 2015-12-30
RU2619944C2 (ru) 2017-05-22
JP2014162794A (ja) 2014-09-08
CA2900322C (en) 2019-03-26
KR20170094012A (ko) 2017-08-16
HUE054212T2 (hu) 2021-08-30
ES2694787T3 (es) 2018-12-27
SG11201505680RA (en) 2015-09-29
HK1211032A1 (en) 2016-05-13
JP6381016B2 (ja) 2018-08-29
TW201803872A (zh) 2018-02-01
CY1120734T1 (el) 2019-12-11
AR094842A1 (es) 2015-09-02
EP3431475B1 (en) 2021-04-07
KR20150107872A (ko) 2015-09-23
US20180065964A1 (en) 2018-03-08
WO2014128588A1 (en) 2014-08-28
MX2019003605A (es) 2019-06-17
TR201816077T4 (tr) 2018-11-21
IL240277A0 (en) 2015-09-24
US20160002223A1 (en) 2016-01-07
TWI633103B (zh) 2018-08-21
CN111253394A (zh) 2020-06-09
US10723730B2 (en) 2020-07-28
AU2014220354B2 (en) 2018-02-01
ES2869277T3 (es) 2021-10-25
NZ710138A (en) 2020-09-25
AU2014220354A1 (en) 2015-08-06
TWI670269B (zh) 2019-09-01
JP2019116512A (ja) 2019-07-18
HK1248217A1 (zh) 2018-10-12
BR112015019508A8 (pt) 2019-11-19
CN105008357A (zh) 2015-10-28
CY1124068T1 (el) 2022-05-27
MX2015010858A (es) 2015-12-03
MX363715B (es) 2019-03-29
SI2958916T1 (sl) 2018-11-30
PT3431475T (pt) 2021-05-13
DK2958916T3 (en) 2018-11-12
BR112015019508A2 (pt) 2017-07-18
KR101858913B1 (ko) 2018-05-16
JP6524152B2 (ja) 2019-06-05
PL2958916T3 (pl) 2019-01-31
CA2900322A1 (en) 2014-08-28
PT2958916T (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
HK1211032A1 (en) Solid forms of a selective cdk4/6 inhibitor cdk4/6
IL285528A (en) A process for preparing a pde4 inhibitor
HK1214818A1 (zh) 選擇性的 抑制劑
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
GB201317609D0 (en) Inhibitor compounds
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
HRP20181876T1 (hr) Inhibitor za retinokoroidalne poremećaje
HK1226072A1 (zh) 作為bcl-3抑制劑的2-苯甲酰氨基苯甲酰胺衍生物
GB201321328D0 (en) Inhibitor compounds
GB201305503D0 (en) Inhibitor
GB201307906D0 (en) Corrosion inhibitor